ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $181,073,802 | -22.5% | 5,079,209 | +0.2% | 0.01% | -16.7% |
| Q2 2023 | $233,741,953 | +19.6% | 5,067,027 | +4.0% | 0.01% | 0.0% |
| Q1 2023 | $195,421,575 | -2.7% | 4,873,356 | +12.4% | 0.01% | 0.0% |
| Q4 2022 | $200,925,935 | +23.5% | 4,336,843 | +10.4% | 0.01% | 0.0% |
| Q3 2022 | $162,645,000 | -24.2% | 3,927,639 | +9.2% | 0.01% | -14.3% |
| Q2 2022 | $214,633,000 | -14.1% | 3,597,584 | +4.6% | 0.01% | 0.0% |
| Q1 2022 | $249,862,000 | -14.7% | 3,440,671 | -1.3% | 0.01% | 0.0% |
| Q4 2021 | $293,025,000 | -5.8% | 3,484,652 | +1.0% | 0.01% | -22.2% |
| Q3 2021 | $311,205,000 | -6.5% | 3,450,553 | -1.2% | 0.01% | 0.0% |
| Q2 2021 | $332,957,000 | -46.5% | 3,491,941 | -36.1% | 0.01% | -50.0% |
| Q1 2021 | $621,923,000 | -15.0% | 5,462,185 | +3.3% | 0.02% | -21.7% |
| Q4 2020 | $731,947,000 | +85.2% | 5,287,476 | +9.9% | 0.02% | +53.3% |
| Q3 2020 | $395,268,000 | +2.9% | 4,809,197 | -2.1% | 0.02% | 0.0% |
| Q2 2020 | $384,111,000 | +89.4% | 4,910,666 | +7.6% | 0.02% | +50.0% |
| Q1 2020 | $202,757,000 | +0.3% | 4,563,531 | -3.6% | 0.01% | +25.0% |
| Q4 2019 | $202,147,000 | +2.2% | 4,733,084 | +2.3% | 0.01% | 0.0% |
| Q3 2019 | $197,868,000 | -29.4% | 4,625,207 | +4.7% | 0.01% | -33.3% |
| Q2 2019 | $280,430,000 | -14.8% | 4,416,215 | -6.9% | 0.01% | -20.0% |
| Q1 2019 | $329,138,000 | +69.1% | 4,745,363 | +6.0% | 0.02% | +50.0% |
| Q4 2018 | $194,652,000 | -41.4% | 4,476,812 | +2.8% | 0.01% | -28.6% |
| Q3 2018 | $332,340,000 | -1.5% | 4,353,403 | -0.8% | 0.01% | -12.5% |
| Q2 2018 | $337,408,000 | +56.4% | 4,389,350 | +3.8% | 0.02% | +60.0% |
| Q1 2018 | $215,720,000 | +24.6% | 4,230,627 | +13.4% | 0.01% | +25.0% |
| Q4 2017 | $173,086,000 | -13.6% | 3,731,887 | -0.8% | 0.01% | -20.0% |
| Q3 2017 | $200,368,000 | -7.8% | 3,762,084 | +7.6% | 0.01% | -16.7% |
| Q2 2017 | $217,237,000 | +1.2% | 3,497,591 | +10.4% | 0.01% | 0.0% |
| Q1 2017 | $214,637,000 | +98357.3% | 3,166,680 | +102249.1% | 0.01% | – |
| Q4 2016 | $218,000 | -27.6% | 3,094 | -27.1% | 0.00% | – |
| Q3 2016 | $301,000 | +55.2% | 4,244 | +6.8% | 0.00% | – |
| Q2 2016 | $194,000 | +22.0% | 3,973 | +58.5% | 0.00% | – |
| Q1 2016 | $159,000 | -96.2% | 2,506 | -93.3% | 0.00% | -100.0% |
| Q4 2015 | $4,195,000 | +2.8% | 37,398 | -11.7% | 0.01% | 0.0% |
| Q3 2015 | $4,079,000 | +4286.0% | 42,354 | +4569.7% | 0.01% | – |
| Q2 2015 | $93,000 | +830.0% | 907 | +443.1% | 0.00% | – |
| Q1 2015 | $10,000 | +42.9% | 167 | 0.0% | 0.00% | – |
| Q4 2014 | $7,000 | -22.2% | 167 | 0.0% | 0.00% | – |
| Q3 2014 | $9,000 | +28.6% | 167 | 0.0% | 0.00% | – |
| Q2 2014 | $7,000 | -98.7% | 167 | -98.5% | 0.00% | -100.0% |
| Q1 2014 | $531,000 | – | 10,867 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |